These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19289328)

  • 21. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
    Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
    Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.
    Brillanti S; Garson J; Foli M; Whitby K; Deaville R; Masci C; Miglioli M; Barbara L
    Gastroenterology; 1994 Sep; 107(3):812-7. PubMed ID: 7521308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated hepatic transaminases associated with the use of interferon alfacon-1 and ribavirin.
    Kleppinger EL; Ragan AP
    Am J Health Syst Pharm; 2009 Mar; 66(5):465-8. PubMed ID: 19233994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
    Fuhrmann V; Kramer L; Bauer E; Laferl H; Tucek G; Dekan G; Schenk P
    Dig Dis Sci; 2004; 49(11-12):1966-70. PubMed ID: 15628735
    [No Abstract]   [Full Text] [Related]  

  • 25. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
    Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
    J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
    Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
    Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.
    Ryan P; Resino S; Miralles P; Cosín J; López JC; Moreno S; Catalán P; Ramírez M; Gutiérrez I; Berenguer J
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):176-81. PubMed ID: 20577091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Severe ocular bacterial infection associated with pegylated interferon and ribavirin treatment for hepatitis C].
    Khalil A; Gonzalez F; El Riachy E; Lucidarme D; Filoche B
    Gastroenterol Clin Biol; 2005 Nov; 29(11):1187-8. PubMed ID: 16505773
    [No Abstract]   [Full Text] [Related]  

  • 29. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.
    Sylvestre DL; Disston AR; Bui DP
    J Viral Hepat; 2003 Nov; 10(6):467-70. PubMed ID: 14633182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis.
    Fabris P; Betterle C; Greggio NA; Zanchetta R; Bosi E; Biasin MR; de Lalla F
    J Hepatol; 1998 Mar; 28(3):514-7. PubMed ID: 9551692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone.
    Le V; Bader T; Fazili J
    Nat Clin Pract Gastroenterol Hepatol; 2009 Jan; 6(1):57-60. PubMed ID: 19029995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.
    Fujioka T; Honda M; Yoshizaki T; Ogawa M; Matsuno H; Shimokawa K; Koyama K
    Intern Med; 2010; 49(18):1987-90. PubMed ID: 20847504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
    Obołończyk Ł; Siekierska-Hellmann M; Wiśniewski P; Lewczuk A; Berendt-Obołończyk M; Lakomy A; Michalska Z; Radowska D; Moszkowska G; Bianek-Bodzak A; Sworczak K
    Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):842-849. PubMed ID: 29039351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
    Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
    J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.
    Chung YH; Shong YK
    Am J Gastroenterol; 1993 Feb; 88(2):244-7. PubMed ID: 8424429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
    Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
    Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment.
    Elloumi H; Houissa F; Hadj NB; Gargouri D; Romani M; Kharrat J; Ghorbel A
    World J Gastroenterol; 2007 Oct; 13(40):5411-2. PubMed ID: 17879419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.